Tale from the Crypt: Belantamab Mafodotin
OncoPharm
00:00
Research opportunities and real-world dosing
John Bizarro suggests studies on lower starting doses, real-world effectiveness, and interventions to reduce keratopathy.
Play episode from 12:52
Transcript
